Introduction: The aim of this study was to compare survival in patients with Alzheimer's disease (AD) and patients with dementia with Lewy bodies (DLB). Since anamnestic and retrospective information about disease duration are unreliable variables, we measured survival from a fixed cognitive level. Methods: Survival time was measured from the reported disease onset, from the time of diagnosis, from Mini-Mental State Examination (MMSE) 20 ± 1, and from MMSE 17 ± 1. Results: Survival time was significantly shorter in the DLB group compared to the AD group both from the time of diagnosis and from the cognitive levels of 20 and 17 on the MMSE. There was no difference in survival when measured from the reported disease onset. Discussion: Our findings indicate that DLB patients have a more malignant clinical course. Our method of investigating survival in a cognitively homogenous population may gain scientific power. Reliable methods to predict survival and the clinical course are of great value for patients, caregivers, doctors, and society.

1.
Noale M, Maggi S, Minicuci N, Marzari C, Destro C, Farchi G, Scafato E, Baldereschi M, Di Carlo A, Crepaldi G: Dementia and disability: impact on mortality - the Italian Longitudinal Study on Aging. Dement Geriatr Cogn Disord 2003;16:7-14.
2.
Guhne U, Matschinger H, Angermeyer MC, Riedel-Heller SG: Incident dementia cases and mortality: results of the Leipzig Longitudinal Study of the Aged (LEILA75+). Dement Geriatr Cogn Disord 2006;22:185-193.
3.
Guehne U, Riedel-Heller S, Angermeyer MC: Mortality in dementia. Neuroepidemiology 2005;25:153-162.
4.
Bianchetti A, Scuratti A, Zanetti O, Binetti G, Frisoni GB, Magni E, Trabucchi M: Predictors of mortality and institutionalization in Alzheimer disease patients 1 year after discharge from an Alzheimer dementia unit. Dementia 1995;6:108-112.
5.
Landi F, Gambassi G, Lapane KL, Sgadari A, Mor V, Bernabei R: Impact of the type and severity of dementia on hospitalization and survival of the elderly. The SAGE Study Group. Dement Geriatr Cogn Disord 1999;10:121-129.
6.
Schmidt C, Redyk K, Meissner B, Krack L, von Ahsen N, Roeber S, Kretzschmar H, Zerr I: Clinical features of rapidly progressive Alzheimer's disease. Dement Geriatr Cogn Disord 2010;29:371-378.
7.
Koedam EL, Pijnenburg YA, Deeg DJ, Baak MM, van der Vlies AE, Scheltens P, van der Flier WM: Early-onset dementia is associated with higher mortality. Dement Geriatr Cogn Disord 2008;26:147-152.
8.
Magierski R, Kloszewska I, Sobow TM: The influence of vascular risk factors on the survival rate of patients with dementia with Lewy bodies and Alzheimer disease. Neurol Neurochir Pol 2010;44:139-147.
9.
Jellinger KA, Wenning GK, Seppi K: Predictors of survival in dementia with Lewy bodies and Parkinson dementia. Neurodegener Dis 2007;4:428-430.
10.
Bostrom F, Hansson O, Blennow K, Gerhardsson L, Lundh T, Minthon L, Zetterberg H, Londos E: Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2009;28:314-319.
11.
Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O: CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 2010;74:1531-1537.
12.
Han L, Cole M, Bellavance F, McCusker J, Primeau F: Tracking cognitive decline in Alzheimer's disease using the Mini-Mental State Examination: a meta-analysis. Int Psychogeriatr 2000;12:231-247.
13.
Ballard C, O'Brien J, Morris CM, Barber R, Swann A, Neill D, McKeith I: The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. Int J Geriatr Psychiatry 2001;16:499-503.
14.
Helmes E, Bowler JV, Merskey H, Munoz DG, Hachinski VC: Rates of cognitive decline in Alzheimer's disease and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2003;15:67-71.
15.
Lopez OL, Wisniewski S, Hamilton RL, Becker JT, Kaufer DI, DeKosky ST: Predictors of progression in patients with AD and Lewy bodies. Neurology 2000;54:1774-1779.
16.
Williams MM, Xiong C, Morris JC, Galvin JE: Survival and mortality differences between dementia with Lewy bodies vs. Alz-heimer disease. Neurology 2006;67:1935-1941.
17.
Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, Thal LJ: Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 1998;51:351-357.
18.
Stavitsky K, Brickman AM, Scarmeas N, Torgan RL, Tang MX, Albert M, Brandt J, Blacker D, Stern Y: The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease. Arch Neurol 2006;63:1450-1456.
19.
Armstrong TP, Hansen LA, Salmon DP, Masliah E, Pay M, Kunin JM, Katzman R: Rapidly progressive dementia in a patient with the Lewy body variant of Alzheimer's disease. Neurology 1991;41:1178-1180.
20.
Galvin JE: Dementia with Lewy bodies. Arch Neurol 2003;60:1332-1335.
21.
Galvin JE, Lee VM, Trojanowski JQ: Synucleinopathies: Clinical and pathological implications. Arch Neurol 2001;58:186-190.
22.
Hanyu H, Sato T, Hirao K, Kanetaka H, Sakurai H, Iwamoto T: Differences in clinical course between dementia with Lewy bodies and Alzheimer's disease. Eur J Neurol 2009;16:212-217.
23.
Heyman A, Fillenbaum GG, Gearing M, Mirra SS, Welsh-Bohmer KA, Peterson B, Pieper C: Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: consortium to establish a registry for Alzheimer's disease, part XIX. Neurology 1999;52:1839-1844.
24.
Walker Z, Allen RL, Shergill S, Mullan E, Katona CL: Three years survival in patients with a clinical diagnosis of dementia with Lewy bodies. Int J Geriatr Psychiatry 2000;15:267-273.
25.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
26.
Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, Teri L, Kukull WA: Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004;140:501-509.
27.
Brookmeyer R, Corrada MM, Curriero FC, Kawas C: Survival following a diagnosis of Alzheimer disease. Arch Neurol 2002;59:1764-1767.
28.
Zanetti O, Solerte SB, Cantoni F: Life expectancy in Alzheimer's disease (AD). Arch Gerontol Geriatr 2009;49(suppl 1):237-243.
29.
Cercy SP, Bylsma FW: Lewy bodies and progressive dementia: a critical review and meta-analysis. J Int Neuropsychol Soc 1997;3:179-194.
30.
Kraemer HC, Taylor JL, Tinklenberg JR, Yesavage JA: The stages of Alzheimer's disease: a reappraisal. Dement Geriatr Cogn Disord 1998;9:299-308.
31.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
32.
Wallin AK, Andreasen N, Eriksson S, Batsman S, Nasman B, Ekdahl A, Kilander L, Grut M, Ryden M, Wallin A, Jonsson M, Olofsson H, Londos E, Wattmo C, Eriksdotter Jonhagen M, Minthon L: Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord 2007;23:150-160.
33.
McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
34.
Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD: An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology 1990;40:763-766.
35.
Rosenberg CK, Cummings TJ, Saunders AM, Widico C, McIntyre LM, Hulette CM: Dementia with Lewy bodies and Alzheimer's disease. Acta Neuropathol 2001;102:621-626.
36.
Collerton D, Burn D, McKeith I, O'Brien J: Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord 2003;16:229-237.
37.
Metzler-Baddeley C: A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer's disease and Parkinson's disease with dementia. Cortex 2007;43:583-600.
38.
Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm AL, Haglund A, Zhang R, Schindler R: 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006;21:353-363.
39.
Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR: Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003;51:937-944.
40.
Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST: Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72:310-314.
41.
Wallin AK, Gustafson L, Sjogren M, Wattmo C, Minthon L: Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy. Dement Geriatr Cogn Disord 2004;18:197-206.
42.
Kaufer DI: Pharmacologic treatment expectations in the management of dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004;17(suppl 1):32-39.
43.
Levy R, Eagger S, Griffiths M, Perry E, Honavar M, Dean A, Lantos P: Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 1994;343:176.
44.
Aarsland D, Bronnick K, Karlsen K: Donepezil for dementia with Lewy bodies: a case study. Int J Geriatr Psychiatry 1999;14:69-72.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.